Brief: Cipla Expands U.S. Respiratory Portfolio With Approval Of Nintedanib Capsules (100Mg & 150Mg) For Idiopathic Pulmonary Fibrosis
03/04/2026 04:12
April 2 (Reuters) - Cipla Ltd CIPL.NS: CIPLA EXPANDS U.S. RESPIRATORY PORTFOLIO WITH APPROVAL OF NINTEDANIB CAPSULES (100MG & 150MG) FOR IDIOPATHIC PULMONARY FIBROSIS Source text: ID:nPn6WdvDya Further company coverage: CIPL.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate